for the VISTA-16 Investigators IMPORTANCE Secretory phospholipase A 2 (sPLA 2 ) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA 2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown.
D espite a high rate of use of contemporary therapies, patients with acute coronary syndrome (ACS) face a substantial risk of early, recurrent adverse cardiovascular events. 1 Increasing evidence supports a potential role of inflammation in the progression and clinical instability of coronary heart disease. 2 Necropsy studies show inflammatory cells within atherosclerotic plaques, 3 and clinical outcomes trials
show an association between systemic inflammatory markers and cardiovascular risk. 4 Conversely, reductions in inflammatory markers associate with reductions in cardiovascular events in clinical trials and may contribute to the benefit of statins. 4 These observations provide a rationale to test novel agents that target specific inflammatory factors implicated in atherosclerosis to determine if it reduces cardiovascular risk. 5 The secretory phospholipase A 2 (sPLA 2 ) family of enzymes hydrolyze fatty acids of glycophospholipids, generating bioactive lipid species involved in inflammation. 6 However, although some sPLA 2 isoforms are proatherogenic (groups IIA and V), other isoforms are protective (group X). 7 Considerable evidence implicates a potential role for groups IIA and V sPLA 2 in cardiovascular disease. Higher circulating levels of sPLA 2 -IIA concentration and activity associate with cardiovascular risk in asymptomatic individuals and patients with established coronary disease. 8 Pathologic studies demonstrate the presence of sPLA 2 isoforms groups IIA, III, V, and X in atherosclerotic lesions and myocardial regions that have sustained ischemic injury. 6, 9, 10 These observations have stimulated interest in the potential value of sPLA 2 inhibition as a cardioprotective strategy. 5 Varespladib methyl is a nonspecific pan-sPLA 2 inhibitor with favorable effects on atherosclerotic lesions in animal studies. 11 Initial studies demonstrated that varespladib reduced levels of sPLA 2 -IIA by more than 90%, in addition to lowering low-density lipoprotein cholesterol (LDL-C) and Creactive protein (CRP) in patients with stable coronary disease and ACS. [12] [13] [14] The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) study was designed to evaluate the effects of varespladib on cardiovascular risk in patients with ACS. 15 
Methods

Study Population
Details of the study design and study protocol have been published previously. 15 Patients aged 40 years or older hospitalized with an ACS who provided written, informed consent were eligible to participate. Documentation of ACS required either (1) elevation of biomarkers accompanied by symptoms of acute myocardial ischemia and/or new or presumed new ischemic electrocardiographic abnormalities or (2) symptoms in combination with new or presumed new electrocardiographic changes in patients without elevated biomarkers. Patients were also required to have 1 additional risk factor for recurrent events, including diabetes, metabolic syndrome, a highdensity lipoprotein cholesterol (HDL-C) level of less than 42 mg/dL (to convert to millimoles per liter, multiply by 0.0259), calculated glomerular filtration rate of less than 60 mL/min, peripheral vascular disease, prior history of ischemic stroke, or transient ischemic attack, myocardial infarction (MI), or coronary revascularization. Patients were excluded from enrollment if LDL-C measured before the index ACS event was not at target levels according to local guidelines, despite current treatment with the maximum labeled dose of a statin. Other key exclusion criteria included advanced congestive heart failure, glycated hemoglobin value of at least 11% (to convert to proportion of total hemoglobin, multiply by 0.01), malignancy, severe liver or renal disease, malignancy, statin intolerance, and fasting triglyceride levels of at least 400 mg/dL (to convert to millimoles per liter, multiply by 0.0113).
Study Procedures
The protocol specified that enrolled patients be treated with individualized, evidence-based management of ACSs, including diet and atorvastatin at a dose of at least 20 mg. Patients who met all inclusion criteria were randomized within 96 hours of presentation of the index event in 
Study Outcomes
The primary efficacy outcome was a composite of cardiovascular mortality, nonfatal MI, nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization. Secondary efficacy outcomes included the composite of cardiovascular mortality, nonfatal MI, and nonfatal stroke; each component of the primary outcome; total mortality; and changes in circulating lipid and inflammatory markers. All investigator-reported outcomes were adjudicated by a central committee at the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).
Statistical Analysis
Primary efficacy analysis was based on time to first occurrence of any positively adjudicated primary end point event by intention-to-treat, including all events in all patients from randomization to trial termination. The trial was designed to enroll 6500 patients, assuming an 8.5% primary end point event rate in the placebo group, with 80% power to detect a 25% reduction in the relative risk of the varespladib group, necessitating the adjudication of 385 primary end point events. An interim end point analysis for futility was specified at approximately 50% of the required primary end point events.
Estimates of hazard ratios (HRs) and 95% CIs for varespladib compared with placebo were calculated by Cox proportional hazards regression models. Continuous data are presented as
Results
Study Population
A total of 5145 patients were enrolled at 362 sites in 17 countries between June 1, 2010, and March 7, 2012 , and entered into the intention-to-treat analysis. The patient disposition during the study is shown in Figure 1 . The qualifying ACS event was biomarker positive in 85% of the patients. The median (interquartile range [IQR] ) time from presentation with the index event to randomization and first study drug administration was 57 (39-76) hours. Baseline characteristics of patients at randomization were well matched in the 2 treatment groups ( Table 1) . A high rate of cardiovascular risk factors and established atherosclerotic disease was observed in both groups. Before the index ACS event, 36% of patients had been treated with a lipid-modifying agent. At randomization, patients were well treated in both groups with a high rate of use of antiplatelet agents, statins, β-blockers, angiotensin-converting enzyme inhibitors, or receptor blockers (see eTable 1 in the Supplement). Coronary revascularization in response to the index event was performed in 80% of the patients. At randomization, mean LDL-C was 105 mg/dL and HDL-C was 43 mg/dL. Median (IQR) CRP was 10.4 (4.0-28.7) mg/L in the placebo group and 11.4 (4.5-33.0) mg/L in the varespladib group. (To convert CRP to nmol/L, multiply by 9.524.) On March 9, 2012 , at the prespecified interim analysis, when 212 primary outcomes had been recorded in 5012 randomized patients, the independent data and safety monitoring board recommended termination of the trial for futility according to predetermined criteria. The executive steering committee and sponsor (Anthera Pharmaceuticals) accepted this recommendation and terminated the trial on this date, with median (IQR) patient follow-up of 16.1 (13.4-16.4) weeks. Patients were treated for a mean (SD) of 13.4 (4.4) weeks. The mean (SD) follow-up of patients for the treatment period was 13.5 (4.6) weeks. All 5145 patients were included in the 16-week analysis. Time to event was calculated from randomization date to the date of the event, or censored at the last known follow-up for each patient if no event occurred. Only 1588 patients were contacted for the 6-month assessment.
Before study termination, premature discontinuation of treatment for reasons other than death occurred in 11.0% of the patients receiving varespladib and 10.4% of the patients receiving placebo. During treatment, 96% of patients in both groups remained at least 80% adherent with prescribed study drug doses. In the varespladib and placebo groups, 4.2% and 3.7%, respectively, of patients withdrew consent and an additional 0.8% and 1.1%, respectively, were lost to follow-up with unknown final vital status.
Biochemical Parameters
Changes in biochemical parameters during the course of the study are shown in Figure 2 . Per protocol, atorvastatin was used (P = .008). At week 16, the mean LDL-C was 69.1 mg/dL in the varespladib group and 73.8 mg/dL in the placebo group. During assigned treatment, levels of triglycerides and HDL-C did not differ between groups. The CRP levels were initially very 
Clinical Outcomes
The primary outcome of cardiovascular mortality, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization occurred in 6.1% of patients treated with varespladib and 5.1% of patients treated with placebo (HR, 1.25; 95% CI, 0.97-1.61; log-rank P = .08) ( Table 2 ). The composite secondary outcome of cardiovascular mortality, MI, and stroke occurred in 4.6% of patients in the varespladib group and 3.8% of patients in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). This was due primarily to a greater incidence of MI in the varespladib group compared with the placebo group (3.4% vs 2.2%; HR, 1.66; 95% CI, 1.16-2.39; P = .005) (Figure 3) . Cardiovascular mortality at the end of the randomized treatment period was nonsignificantly greater in the varespladib group (1.5% vs 1.4%; P = .54), although risks of stroke (0.4% vs 0.6%; P = .81) and hospitalization for unstable angina (1.9% vs 1.4%; P = .47) were similar in both groups. There was no subgroup in which varespladib reduced risk. However, greater rates of MI with varespladib were observed in patients who did not undergo percutaneous coronary intervention, meeting statistical significance for heterogeneity (P = .04). Furthermore, there was a higher rate of MI associated with varespladib among patients whose index event was not a STEMI, although this did not reach statistical significance (P = .06 for heterogeneity) (Figure 4) . At 6 months after discontinuation of study treatment, allcause mortality in those patients whose survival status was established was 2.7% in the varespladib group and 2.0% in the placebo group (P = .15).
Safety
Numbers of adverse events and serious adverse events are reported in eTable 2 in the Supplement. Discontinuation of study treatment for adverse events occurred in 2.8% of patients in the varespladib group and 1.4% of patients in the placebo group. There was an excess of alanine transaminase elevations more than 3 times the upper limit of normal during the treatment 
Discussion
Despite experimental and observational clinical data suggesting that pan-inhibition of sPLA 2 would exert beneficial cardiovascular effect, the VISTA-16 trial provides evidence to the contrary. Despite lower achieved levels of LDL-C and CRP, there was no evidence of a beneficial reduction in the primary cardiovascular outcome. In contrast, treatment with varespladib caused an excess of MI and the composite of cardiovascular mortality, MI, and stroke. Consequently, these findings suggest that short-term sPLA 2 inhibition with varespladib is harmful following ACS.
The lack of any indication of cardiovascular benefit with varespladib contradicts the favorable effects on cardiovascular biomarkers in patients with ACS. Initial clinical experience with varespladib consistently demonstrated beneficial effects on lipid and inflammatory biomarkers, which theoretically should have translated to a lower propensity to plaque rupture. [12] [13] [14] We conducted the VISTA-16 trial because of the established link between sPLA 2 and vascular inflammation, as well as preclinical evidence for benefit in ischemia reperfusion injury. 5 Favorable effects of varespladib on LDL-C and CRP were again demonstrated in the present trial, suggesting that other unfavorable consequences of sPLA 2 inhibition or other unmeasured effects of varespladib influenced the clinical outcomes of treatment. Possible explanations for the unfavorable outcomes include potentially inadequate penetration of varespladib into vascular cells to inhibit pro-inflammatory intracellular mediators. Alternatively, varespladib may have abrogated the effects of both pro-atherogenic (IIA and V) and antiatherogenic sPLA 2 The primary efficacy outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, and unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Patients were randomized to receive either varespladib (500 mg/d) or placebo for 16 weeks. HR indicates hazard ratio. Y-axis scale shown in blue indicates range from 0% to 4%. The primary efficacy outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, and unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Patients were randomized to receive either varespladib (500 mg/d) or placebo for 16 weeks. Non-STEMI indicates non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction. Because of missing data, number of patients in the subgroups do not sum to total number of patients randomized to receive placebo or varespladib.
isoforms. 6, 7 Our findings with sPLA 2 inhibition reemphasize that identification of a circulating marker of cardiovascular risk does not necessarily imply that pharmacologic suppression or inhibition of the marker will reduce risk. The failure to demonstrate any benefit is supported by a recent report from Mendialian randomization studies concluding that sPLA 2 does not play a causative role in coronary disease 16 ; however, such studies cannot necessarily predict the result of a pharmacologic intervention in patients with established coronary disease. Ultimately, most therapies must be tested using careful human randomized clinical trials.
The precise mechanism underlying the adverse effect on the rate of MI with varespladib remains unknown. Recurrent MI in patients with a recent ACS often results from ongoing episodes of plaque rupture and thrombosis, often at sites remote from the lesion responsible for the initial event. The increased rate of MI observed early in the trial might also suggest that the drug may have induced a prothrombotic state. However, we observed no excess rate of early stent thrombosis in the varespladib group. In fact, we observed less harm for MI with varespladib in patients who had undergone percutaneous coronary intervention for the index ACS event and in patients whose initial presentation was with STEMI. There currently exists no external information regarding potential interactions between either sPLA 2 activity or varespladib and factors that influence the coagulation cascade or platelet function. Given that other therapies that modulate prostaglandin metabolites have been reported to be associated with an excess rate of MI, 17 the potential effect of the varespladib molecule and sPLA 2 inhibition on thrombotic and fibrinolytic pathways, in addition to plaque stability, require further investigation. The findings may have implications for targeting other inflammatory pathways as strategies to reduce cardiovascular risk. Although the role of vascular inflammation in atherosclerosis is widely accepted, there is at present no evidence to our knowledge that targeting any specific inflammatory factor will attenuate cardiovascular risk. The complexity and redundancy of inflammatory pathways may confound such efforts. 8 Evidence by other studies indicates that interventions targeting prostaglandin inflammatory pathways, such as rofecoxib, are harmful rather than protective against coronary heart disease. 17 Nevertheless, other anti-inflammatory agents, including inhibitors of lipoprotein-associated phospholipase A 2 , are undergoing evaluation in large clinical trials. [18] [19] [20] A number of limitations should be noted with regard to our study. Survival status at 6 months was not established in a majority of patients. Accordingly, we cannot exclude that the increased rate of MI with varespladib did not ultimately result in an excess mortality rate. Given that varespladib is a pansPLA 2 inhibitor, it is unknown whether a more selective agent would be beneficial. Patients were not selected for randomization on the basis of their underlying sPLA 2 concentration or activity. The VISTA-16 trial was an evaluation of the effect of sPLA 2 inhibition with varespladib in the first few months following an ACS. It is unknown whether such a strategy would be more likely to be protective in a more chronic stage of the disease. However, the finding of an excess risk of MI with varespladib makes it unlikely that this will be investigated.
The administrative actions of the sponsor and the timelines involved with the dissemination of data from this clinical trial require further comment. The sponsor took the appropriate scientific and ethical course of action to accept the recommendation by the data and safety monitoring board and prematurely stop the study for futility on March 9, 2012. 21 Although the study protocol stipulated that survival status would be determined for all patients who participated in the study, data were collected by the sponsor for only 1588 of the 5145 enrolled patients. In addition, the study steering committee and the investigators did not receive the full database for analysis until May 10, 2013 , approximately 1 month after the sponsor's compound license expired and was returned to the original developer of the compound.
Conclusions
In conclusion, sPLA 2 inhibition with varespladib administration did not reduce cardiovascular ischemic complications and resulted in an excess rate of MI and the composite of cardiovascular mortality, MI, and stroke in patients with ACS. Whether this represents an adverse effect of the varespladib molecule or a consequence of pan-sPLA 2 inhibition remains to be determined.
